Serum lactate dehydrogenase and survival following cancer diagnosis

Wahyu Wulaningsih; Lars Holmberg; Hans Garmo; Håkan Malmstrom; Mats Lambe; Niklas Hammar; Göran Walldius; Ingmar Jungner; Tony Ng; Mieke Van Hemelrijck

doi:10.1038/bjc.2015.361

Serum lactate dehydrogenase and survival following cancer diagnosis

Wahyu Wulaningsih^*, Lars Holmberg, Hans Garmo, Håkan Malmstrom, Mats Lambe, Niklas Hammar, Göran Walldius, Ingmar Jungner, Tony Ng, Mieke Van Hemelrijck

^*Corresponding author for this work

Cell Imaging

Research output: Contribution to journal › Article › peer-review

86 Citations (Scopus)

Abstract

Background:There is evidence that high level of serum lactate dehydrogenase (LDH) is associated with poorer overall survival in several malignancies, but its link to cancer-specific survival is unclear.Methods:A total of 7895 individuals diagnosed with cancer between 1986 and 1999 were selected for this study. Multivariable Cox proportional hazards regression was used to assess overall and cancer-specific death by the z-score and clinical categories of serum LDH prospectively collected within 3 years before diagnosis. Site-specific analysis was performed for major cancers. Analysis was repeated by different lag times between LDH measurements and diagnosis.Results:At the end of follow-up, 5799 participants were deceased. Hazard ratios (HRs) and 95% confidence intervals (CIs) for overall and cancer-specific death in the multivariable model were 1.43 (1.31-1.56) and 1.46 (1.32-1.61), respectively, for high compared with low prediagnostic LDH. Site-specific analysis showed high LDH to correlate with an increased risk of death from prostate, pulmonary, colorectal, gastro-oesophageal, gynaecological and haematological cancers. Serum LDH assessed within intervals closer to diagnosis was more strongly associated with overall and cancer-specific death.Conclusions:Our findings demonstrated an inverse association of baseline serum LDH with cancer-specific survival, corroborating its role in cancer progression.

Original language	English
Pages (from-to)	1389-1396
Number of pages	8
Journal	British Journal of Cancer
Volume	113
Issue number	9
Early online date	15 Oct 2015
DOIs	https://doi.org/10.1038/bjc.2015.361
Publication status	Published - 3 Nov 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2015.361

Cite this

@article{867be02b7fd9469fa6c5a6efd430c4fb,

title = "Serum lactate dehydrogenase and survival following cancer diagnosis",

abstract = "Background:There is evidence that high level of serum lactate dehydrogenase (LDH) is associated with poorer overall survival in several malignancies, but its link to cancer-specific survival is unclear.Methods:A total of 7895 individuals diagnosed with cancer between 1986 and 1999 were selected for this study. Multivariable Cox proportional hazards regression was used to assess overall and cancer-specific death by the z-score and clinical categories of serum LDH prospectively collected within 3 years before diagnosis. Site-specific analysis was performed for major cancers. Analysis was repeated by different lag times between LDH measurements and diagnosis.Results:At the end of follow-up, 5799 participants were deceased. Hazard ratios (HRs) and 95% confidence intervals (CIs) for overall and cancer-specific death in the multivariable model were 1.43 (1.31-1.56) and 1.46 (1.32-1.61), respectively, for high compared with low prediagnostic LDH. Site-specific analysis showed high LDH to correlate with an increased risk of death from prostate, pulmonary, colorectal, gastro-oesophageal, gynaecological and haematological cancers. Serum LDH assessed within intervals closer to diagnosis was more strongly associated with overall and cancer-specific death.Conclusions:Our findings demonstrated an inverse association of baseline serum LDH with cancer-specific survival, corroborating its role in cancer progression.",

author = "Wahyu Wulaningsih and Lars Holmberg and Hans Garmo and H{\aa}kan Malmstrom and Mats Lambe and Niklas Hammar and G{\"o}ran Walldius and Ingmar Jungner and Tony Ng and {Van Hemelrijck}, Mieke",

year = "2015",

month = nov,

day = "3",

doi = "10.1038/bjc.2015.361",

language = "English",

volume = "113",

pages = "1389--1396",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Serum lactate dehydrogenase and survival following cancer diagnosis

AU - Wulaningsih, Wahyu

AU - Holmberg, Lars

AU - Garmo, Hans

AU - Malmstrom, Håkan

AU - Lambe, Mats

AU - Hammar, Niklas

AU - Walldius, Göran

AU - Jungner, Ingmar

AU - Ng, Tony

AU - Van Hemelrijck, Mieke

PY - 2015/11/3

Y1 - 2015/11/3

N2 - Background:There is evidence that high level of serum lactate dehydrogenase (LDH) is associated with poorer overall survival in several malignancies, but its link to cancer-specific survival is unclear.Methods:A total of 7895 individuals diagnosed with cancer between 1986 and 1999 were selected for this study. Multivariable Cox proportional hazards regression was used to assess overall and cancer-specific death by the z-score and clinical categories of serum LDH prospectively collected within 3 years before diagnosis. Site-specific analysis was performed for major cancers. Analysis was repeated by different lag times between LDH measurements and diagnosis.Results:At the end of follow-up, 5799 participants were deceased. Hazard ratios (HRs) and 95% confidence intervals (CIs) for overall and cancer-specific death in the multivariable model were 1.43 (1.31-1.56) and 1.46 (1.32-1.61), respectively, for high compared with low prediagnostic LDH. Site-specific analysis showed high LDH to correlate with an increased risk of death from prostate, pulmonary, colorectal, gastro-oesophageal, gynaecological and haematological cancers. Serum LDH assessed within intervals closer to diagnosis was more strongly associated with overall and cancer-specific death.Conclusions:Our findings demonstrated an inverse association of baseline serum LDH with cancer-specific survival, corroborating its role in cancer progression.

AB - Background:There is evidence that high level of serum lactate dehydrogenase (LDH) is associated with poorer overall survival in several malignancies, but its link to cancer-specific survival is unclear.Methods:A total of 7895 individuals diagnosed with cancer between 1986 and 1999 were selected for this study. Multivariable Cox proportional hazards regression was used to assess overall and cancer-specific death by the z-score and clinical categories of serum LDH prospectively collected within 3 years before diagnosis. Site-specific analysis was performed for major cancers. Analysis was repeated by different lag times between LDH measurements and diagnosis.Results:At the end of follow-up, 5799 participants were deceased. Hazard ratios (HRs) and 95% confidence intervals (CIs) for overall and cancer-specific death in the multivariable model were 1.43 (1.31-1.56) and 1.46 (1.32-1.61), respectively, for high compared with low prediagnostic LDH. Site-specific analysis showed high LDH to correlate with an increased risk of death from prostate, pulmonary, colorectal, gastro-oesophageal, gynaecological and haematological cancers. Serum LDH assessed within intervals closer to diagnosis was more strongly associated with overall and cancer-specific death.Conclusions:Our findings demonstrated an inverse association of baseline serum LDH with cancer-specific survival, corroborating its role in cancer progression.

UR - http://www.scopus.com/inward/record.url?scp=84946494544&partnerID=8YFLogxK

U2 - 10.1038/bjc.2015.361

DO - 10.1038/bjc.2015.361

M3 - Article

AN - SCOPUS:84946494544

SN - 0007-0920

VL - 113

SP - 1389

EP - 1396

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 9

ER -

Serum lactate dehydrogenase and survival following cancer diagnosis

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this